Plastin 3 down-regulation augments the sensitivity of MDA-MB-231 cells to paclitaxel via the p38 MAPK signalling pathway

References

• Goldspiel BR. Clinical overview of the taxanes. Pharmacotherapy. 1997;17:110S–125S.
   PubMed Web of Science ®Google Scholar
• Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991;83:1797–1805.
   PubMed Web of Science ®Google Scholar
• McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111:273–279.
   PubMed Web of Science ®Google Scholar
• Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007;357:1496–1506.
   PubMed Web of Science ®Google Scholar
• Ellis P, Barrett-Lee P, Johnson L, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009;373:1681–1692.
   PubMed Web of Science ®Google Scholar
• Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev. 2008;60:876–885.
   PubMed Web of Science ®Google Scholar
• Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26:57–64.
   PubMed Web of Science ®Google Scholar
• Subbaramaiah K, Hart JC, Norton L, et al. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 and p38 mitogen-activated protein kinase pathways. J Biol Chem. 2000;275:14838–14845.
   PubMed Web of Science ®Google Scholar
• Bacus SS, Gudkov AV, Lowe M, et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene. 2001;20:147–155.
   PubMed Web of Science ®Google Scholar
• Seidman R, Gitelman I, Sagi O, et al. The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. Exp Cell Res. 2001;268:84–92.
   PubMed Web of Science ®Google Scholar
• Lu M, Xiao L, Li Z, et al. The relationship between p38MAPK and apoptosis during paclitaxel resistance of ovarian cancer cells. J Huazhong Univ Sci Technol [Med Sci]. 2007;27:725–728.
   PubMedGoogle Scholar
• Park SH, Seong MA, Lee HY. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells. Oncotarget. 2016;7:8184–8199.
   PubMedGoogle Scholar
• Sanchez-Prieto R, Rojas JM, Taya Y, et al. A role for the p38 mitogen-acitvated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res. 2000;60:2464–2472.
   PubMed Web of Science ®Google Scholar
• Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9:1799–1805.
   PubMed Web of Science ®Google Scholar
• George J, Banik NL, Ray SK. Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. Neurochem Res. 2009;34:66–78.
   PubMed Web of Science ®Google Scholar
• Bretscher A, Weber K. Fimbrin, a new microfilament-associated protein present in microvilli and other cell surface structures. J Cell Biol. 1980;86:335–340.
   PubMed Web of Science ®Google Scholar
• Glenney JR, Jr, Kaulfus P, Matsudaira P, et al. F-actin binding and bundling properties of fimbrin, a major cytoskeletal protein of microvillus core filaments. J Biol Chem 1981;256:9283–9288.
   PubMed Web of Science ®Google Scholar
• Yokobori T, Iinuma H, Shimamura T, et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 2013;73:2059–2069.
   PubMed Web of Science ®Google Scholar
• Ueo H, Sugimachi K, Gorges TM, et al. Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer. Br J Cancer. 2015;112:1519–1526.
   PubMed Web of Science ®Google Scholar
• Hisano T, Ono M, Nakayama M, et al. Increased expression of T-plastin gene in cisplatin-resistant human cancer cells: identification by mRNA differential display. FEBS Lett. 1996;397:101–107.
   PubMed Web of Science ®Google Scholar
• Ikeda H, Sasaki Y, Kobayashi T, et al. The role of T-fimbrin in the response to DNA damage: silencing of T-fimbrin by small interfering RNA sensitizes human liver cancer cells to DNA-damaging agents. Int J Oncol. 2005;27:933–940.
   PubMed Web of Science ®Google Scholar
• Liu H, Ma Y, He HW, et al. SLC9A3R1 stimulates autophagy via BECN1 stabilization in breast cancer cells. Autophagy. 2015;11:2323–2334.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang S, He H, et al. RasGAP-derived peptide 38GAP potentiates the cytotoxicity of cisplatin through inhibitions of Akt, ERK and NF-κB in colon carcinoma HCT116 cells . Cancer Lett. 2011;308:62–70.
   PubMed Web of Science ®Google Scholar
• Giannakakou P, Robey R, Fojo T, et al. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene. 2001;20:3806–3813.
   PubMed Web of Science ®Google Scholar
• Demidenko ZN, Kalurupalle S, Hanko C, et al. Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis. Oncogene. 2008;27:4402–4410.
   PubMed Web of Science ®Google Scholar
• Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 2000;88:2619–2628.
   PubMed Web of Science ®Google Scholar
• Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release. 2013;170:365–372.
   PubMed Web of Science ®Google Scholar
• Walle UK, Walle T. Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos. 1998;26:343–346.
   PubMed Web of Science ®Google Scholar
• Kubler E, Riezman H. Actin and fimbrin are required for the internalization step of endocytosis in yeast. Embo J. 1993;12:2855–2862.
   PubMed Web of Science ®Google Scholar
• Hosseinibarkooie S, Peters M, Torres-Benito L, et al. The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype. Am J Hum Genet. 2016;99:647–665.
   PubMed Web of Science ®Google Scholar
• Bulavin DV, Fornace AJ. Jr., p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res. 2004;92:95–118.
   PubMed Web of Science ®Google Scholar
• Dolado I, Nebreda AR. Regulation of tumorigenesis by p38α MAP kinase. In: Posas F, Nebreda AR, editors. Stress-activated protein kinases. Topics in current genetics. Vol 20. Berlin–Heidelberg (Germany): Springer; 2007. p. 99–128.
   Google Scholar
• Chen L, Mayer JA, Krisko TI, et al. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 2009;69:8853–8861.
   PubMed Web of Science ®Google Scholar
• Kozma SC, Bogaard ME, Buser K, et al. The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. Nucleic Acids Res. 1987;15:5963–5971.
   PubMed Web of Science ®Google Scholar
• Uehara N, Kanematsu S, Miki H, et al. Requirement of p38 MAPK for a cell-death pathway triggered by vorinostat in MDA-MB-231 human breast cancer cells. Cancer Lett. 2012;315:112–121.
   PubMed Web of Science ®Google Scholar
• Kwon YW, Ueda S, Ueno M, et al. Mechanism of p53-dependent apoptosis induced by 3-methylcholanthrene: involvement of p53 phosphorylation and p38 MAPK. J Biol Chem. 2002;277:1837–1844.
   PubMed Web of Science ®Google Scholar
• Gao J, Gao J, Qian L, et al. Activation of p38-MAPK by CXCL4/CXCR3 axis contributes to p53-dependent intestinal apoptosis initiated by 5-fluorouracil. Cancer Biol Ther. 2014;15:982–991.
   PubMed Web of Science ®Google Scholar
• Lamy V, Bousserouel S, Gosse F, et al. Lupulone triggers p38 MAPK-controlled activation of p53 and of the TRAIL receptor apoptotic pathway in human colon cancer-derived metastatic cells. Oncol Rep. 2011;26:109–114.
   PubMed Web of Science ®Google Scholar
• Lukashchuk N, Vousden KH. Ubiquitination and degradation of mutant p53. Mol Cell Biol. 2007;27:8284–8295.
   PubMed Web of Science ®Google Scholar
• De CG, Marcocci ME, Torcia M, et al. Bcl-2 Phosphorylation by p38 MAPK: identification of target sites and biologic consequences. J Biol Chem. 2006;281:21353–21361.
   PubMed Web of Science ®Google Scholar
• Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6:99–104.
   PubMed Web of Science ®Google Scholar
• Schnitzer JE. gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am J Physiol. 1992;262:H246–H254.
   PubMed Web of Science ®Google Scholar
• Minshall RD, Tiruppathi C, Vogel SM, et al. Endothelial cell-surface gp60 activates vesicle formation and trafficking via G(i)-coupled Src kinase signaling pathway. J Cell Biol. 2000;150:1057–1070.
   PubMed Web of Science ®Google Scholar
• Vogel SM, Minshall RD, Pilipovic M, et al. Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1512–L1522.
   PubMed Web of Science ®Google Scholar
• Trieu V, Frankel T, Labao E, et al. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs. taxol. Abstract in the Proceedings of the 96th Annual Meeting of the American Association for Cancer Research; 2005 Apr 16–20; Anaheim, CA. Cancer Res. 2005;65(9 Suppl):1314.
   Google Scholar
• Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem. 2009;78:857–902.
   PubMed Web of Science ®Google Scholar
• Mooren OL, Galletta BJ, Cooper JA. Roles for actin assembly in endocytosis. Annu Rev Biochem. 2012;81:661–686.
   PubMed Web of Science ®Google Scholar
• Pai SI, Lin YY, Macaes B, et al. Prospects of RNA interference therapy for cancer. Gene Ther. 2006;13:464–477.
   PubMed Web of Science ®Google Scholar
• Sugimachi K, Yokobori T, Iinuma H, et al. Aberrant expression of plastin-3 via copy number gain induces the epithelial-mesenchymal transition in circulating colorectal cancer cells. Ann Surg Oncol. 2014;21:3680–3690.
   PubMed Web of Science ®Google Scholar
• Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–4751.
   PubMed Web of Science ®Google Scholar